6 Dec 2021 – H.C. Wainwright Psychedelics Virtual Conference
Small Pharma is participating in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference which is being held virtually on Monday, December 6, 2021. A webcast presentation hosted by Peter Rands, Small Pharma’s Chief Executive Officer, will be available to view on demand beginning on December 6, 2021 at 7:00 a.m ET. Webcast Information: Presenter: Peter […]
Discussions With FDA Provide Guidance For Phase IIb Clinical Trial Design For DMT-assisted Therapy For Major Depressive Disorder
LONDON, Nov. 15, 2021 -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today confirms, following positive discussions with the U.S. Food and Drug Administration (the “FDA”), that preparations are now underway for the U.S. component of its Phase IIb clinical trial for its lead candidate, SPL026, a N,N-dimethyltryptamine (“DMT”) assisted therapy for the treatment of major d
Small Pharma granted fast-track designation from UK regulator for DMT-assisted therapy for Major Depressive Disorder
LONDON, Sept. 21, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder ("MDD").
Companies Compete to Create DMT Therapies
Lucid News has published an article covering the landscape of companies working to create DMT Therapies. Once considered fringe medicine and the domain of maverick clinical researchers, innovators in the psychedelics field are now poised to make a significant contribution to the mental health landscape worldwide. The article covers some of the cutting-edge research being […]
First patient dosed in Phase IIA DMT-assisted therapy clinical trial
LONDON, Sept. 21, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder ("MDD").
Small Pharma successfully completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy.
LONDON, Sept. 21, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder ("MDD").
Small Pharma to headline the 2021 DMT conference: a molecular masterclass
Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that it will headline Microdose’s virtual 2021 DMT Conference as one of the event’s lead sponsors.
Psychedelic solution for depression: British drug firm starts clinical trials of new treatment that sends patients on a hallucinogenic trip
Small Pharma is carrying out clinical trials of a drug based on chemical DMT It is a psychedelic found in plants and animals that produces hallucinations The clinical trials aim to see if it can work with therapy to treat severe depression Assuming it works it could be on the market within the next six years, […]
Powerful hallucinogenic drug used in shamanic rituals is being trialled in the UK as a cure for depression
The hallucinogenic drug DMT is being trialled on British depression patients It is hoped it will help bring relief to those who don’t respond to normal pills Evidence suggests that DMT in combination with talking therapy can help A powerful hallucinogenic drug that has been used in shamanic rituals is being trialled by a British […]
Psychedelic therapy could ‘reset’ depressed brain
A powerful hallucinogenic drug known for its part in shamanic rituals is being trialled as a potential cure for depression for the first time. Participants will be given the drug DMT, followed by talking therapy. It is hoped this could offer an alternative for the significant number of people who don’t respond to conventional pills […]